- Home
- BCLI vs GLTO Comparison
BCLI vs GLTO Comparison
Compare BCLI & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- GLTO
- Stock Information
- Founded
- BCLI 2000
- GLTO 2011
- Country
- BCLI United States
- GLTO Denmark
- Employees
- BCLI N/A
- GLTO N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- GLTO Health Care
- Exchange
- BCLI Nasdaq
- GLTO Nasdaq
- Market Cap
- BCLI 6.4M
- GLTO 6.5M
- IPO Year
- BCLI N/A
- GLTO 2020
- Fundamental
- Price
- BCLI $0.92
- GLTO $2.85
- Analyst Decision
- BCLI Strong Buy
- GLTO Buy
- Analyst Count
- BCLI 1
- GLTO 1
- Target Price
- BCLI $30.00
- GLTO $10.00
- AVG Volume (30 Days)
- BCLI 366.6K
- GLTO 50.5K
- Earning Date
- BCLI 05-13-2025
- GLTO 05-06-2025
- Dividend Yield
- BCLI N/A
- GLTO N/A
- EPS Growth
- BCLI N/A
- GLTO N/A
- EPS
- BCLI N/A
- GLTO N/A
- Revenue
- BCLI N/A
- GLTO N/A
- Revenue This Year
- BCLI N/A
- GLTO N/A
- Revenue Next Year
- BCLI N/A
- GLTO N/A
- P/E Ratio
- BCLI N/A
- GLTO N/A
- Revenue Growth
- BCLI N/A
- GLTO N/A
- 52 Week Low
- BCLI $0.72
- GLTO $2.01
- 52 Week High
- BCLI $10.05
- GLTO $18.50
- Technical
- Relative Strength Index (RSI)
- BCLI 35.85
- GLTO 46.24
- Support Level
- BCLI $1.12
- GLTO $2.36
- Resistance Level
- BCLI $0.82
- GLTO $2.86
- Average True Range (ATR)
- BCLI 0.12
- GLTO 0.29
- MACD
- BCLI 0.01
- GLTO 0.09
- Stochastic Oscillator
- BCLI 36.36
- GLTO 98.59
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.